FDA Approves Cimerli (ranibizumab-eqrn), an Interchangeable Biosimilar to Lucentis

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cimerli (ranibizumab-eqrn) as a biosimilar...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news